References
1. Diagnostic and Statistical Manual of mental disorders - Fourth Edition American Psychiatric Association, 1994.
2. National Institute for Health and Clinical Excellence. Methylphenidate, atomoxetine and dexamfetamine for attention deficit hyperactivity disorder (ADHD) in children and adolescents. March 2006. www.nice.org.uk
3. Scotish intercollegiate guidelines network (SIGN). Management of attention deficit and hyerpkinetic disorders in children and young people: A national clinical guideline. Guideline 112 October 2009. www.sign.ac.uk
4. Pliszka S. Practice Parameter for the Assessment and Treatment of Children and Adolescents With Attention-Deficit/Hyperactivity Disorder. J Am Acad Child Adolesc Psychiatry 2007;46(7) : 894-921.
5. Gaub M, Carlson CL. Gender differences in ADHD: a meta analysis and critical review.J Am Acad Child Adolesc Psychiatry 1997;36: 1036-45.
6. Nutt DJ, et al. Evidence-based guidelines for management of attention-deficit/ hyperactivity disorder in adolescents in transition to adult services and in adults: recommendations from the British Association for Psychopharmacology. J Psychopharmacol 2007;21(1): 10-41.
7. Faraone SV, Perlis RH, Doyle AE, et al. Molecular genetics of attention-deficit/ hyperactivity disorder. Biol Psychiatry 2005; 57: 1313-1323.
8. Castellanos FX, et al. Developmental trajectories of brain volume abnormalities in children and adolescents with attention-deficit/hyperactivity disorder. JAMA 2002; 288(14): 1740-8.
9. Valera EM, et al. Meta-analysis of structural imaging findings in attentiondeficit/ hyperactivity disorder. Biol Psychiatry 2007; 61(12): 1361-9.
10. Spencer TJ, et al. Overview and neurobiology of ADHD. J Clinical Psych 2002; 63(S12): 3-9.
11. Gillberg C, et al. Co-existing disorders in ADHD - implications for diagnosis and intervention. Eur Child Adolesc Psychiatry 2004; 13(Suppl 1):I80-92.
12.Concerta XL 18mg, 27mg and 36 mg summary of product characteristics. Janssen-Cilag Ltd. November 2010.
13.Equasym XL. Summary of Product Characteristics. Shire Pharmaceuticals Ltd. April 2011.
14.Equasym. Summary of Product Characteristics. Shire Pharmaceuticals Ltd. February 2010.
15.Ritalin. Summary of Product Characteristics. Novartis. February 2010.
16.BNF. CNS Stimulants and drugs used for ADHD. March 2011.
17.Strattera. Summary of Product Characteristics. Lilly. September 2009.
18. Kutcher S, et al. International consensus statement on attention deficit hyperactivity disorder (ADHD) and disruptive behaviour disorder: clinical implications and treatment practice suggestions. Eur Neuropsychopharmacol 2004; 14: 11-28.
19. Richardson AJ. Omega-3 fatty acids in ADHD and related neurodevelopmental disorders. Int Rev Psychiatry 2006; 18(2): 155-172.
20.Special Educational Needs (SEN) - A guide for parents and carers. Available at media.education.gov.uk. Accessed 8th June 2011
21. Thompson AE, et al. Children with ADHD transferring to secondary school: Potential difficulties and solutions. Clinical Child Psychology and Psychiatry 2003;8(1): 91-103.
22. Education Act 1996. Available at www.transitioninfonetwork.org.uk. Accessed 8th June 2011
23. Disability discrimination Act 1995 Part 4: Code of practice. Available at nationalstrategies.standards.dcsf.gov.uk. Accessed 8th June 2011
Return to the main menu
ADHD is an abbreviation for Attention Deficit Hyperactivity Disorder. The information provided on this website is not a substitute for professional medical care. As always if you have any concerns about you or your child's health or medication you should consult your specialist or general practitioner. This site is published by Janssen-Cilag Ltd, which is solely responsible for the content. © Janssen-Cilag Ltd. 2007-2013. Last updated March 2013.